local_hospital

Complejo Hospitalario de Jaén

Address
Avda. del Ejército Español 10, 23007 Jaén, Spain

Complejo Hospitalario de Jaén

Complejo Hospitalario de Jaén is a distinguished medical research center conducting innovative clinical trials across diverse therapeutic areas. The institution demonstrates particular expertise in immunotherapy approaches and oncology research, with a focus on developing novel treatment strategies that improve patient outcomes while optimizing safety profiles.

  • Allergic rhinitis and rhinoconjunctivitis management, including cluster-immunotherapy for Olea europaea (olive) pollen allergy
  • HER2-positive early-stage breast cancer treatment with chemotherapy-free, biomarker-guided therapeutic approaches
  • Innovative subcutaneous targeted therapies including trastuzumab-pertuzumab combinations and T-DM1

The center's research portfolio reflects a commitment to personalized medicine and precision treatment strategies. In oncology, investigators are pioneering pathological complete response (pCR)-guided protocols that eliminate traditional chemotherapy while maintaining therapeutic efficacy in HER2-positive breast cancer. Simultaneously, the institution advances allergy research through sophisticated cluster-immunotherapy trials targeting regional allergens, with emphasis on establishing optimal dosing regimens that balance clinical benefit with patient safety and tolerability.

Site Overview

assignment
2
connected trials
corporate_fare
2
sponsors
science
17
IMPs

Activity Indicator

Last 6 months

0
Trials started
0
Trials started 6–12 months ago
2
Total trials linked
Moderately Active
trending_flatStable0%
Mar
Apr
May
Jun
Jul
Aug

Trial Flow

How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.

Therapeutic areaarrow_forwardIMParrow_forwardLifecycle status

Top 2 therapeutic areas and 15 of 17 IMPs, ranked by number of trials.

lock Available on a paid plan

Compounds & Molecules Timeline

The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.

Trial span Ongoing Showing last 8 years
lock Available on a paid plan

Sponsor & Partnership

Top sponsors by active trials, and the ones that have come back for more than one study.

Active trials
0
Sponsors (total)
2
Active sponsors
0

Sponsor Network

Top 10 by active trials.

No sponsors linked to active trials.

Partnership History

Sponsors with repeated collaboration (≥ 2 trials).

No repeated partnerships found.

Sponsor Network Graph

How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.

Country Benchmark

Compared to 567 other sites in Spain

description
Trial volume
2
Outperforms 47% of sites
public
Therapeutic diversity
2areas
Outperforms 49% of sites
groups
Sponsor diversity
2sponsors
Outperforms 49% of sites

Therapeutic Area Benchmark — Spain

Select a therapeutic area to compare against other sites in Spain.

Competitor Comparison

Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.

Country: Spain

Market Share

Country: Spain

Therapeutic Area Market Share

Select a therapeutic area to view its disease coverage breakdown.

Heat Maps & Advanced Analytics

How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.

Other Trials in Complejo Hospitalario de Jaén

lock Showing 1 of 2 trials — the rest is available on a paid plan.

Trial Sponsor Phase Status Start Date End Date
Efficacy and Safety Evaluation of Subcutaneous Cluster Immunotherapy with Allergenic Extract of Olea Europaea Pollen in Moderate-to-Severe Allergic RhinitisROXALL Medizin GmbHPhase IVNot RecruitingSep 2024Oct 2025

IMP list

lock Showing 1 of 17 compounds — the rest is available on a paid plan.

IMP Trials Status First start Last start
Allergenic Extract Of Olea Europaea Pollen Polymerized With Glutaraldehyde1Unknown2024-09-012024-09-01

Request feasibility information

Ask this centre about capacity, equipment and patient population.

Upgrade this site to Business Plan

Own the profile, publish your feasibility data and reach sponsors directly.

Is something out of date?

Tell us what needs correcting and we'll update this profile.

lock Available to Business plan sites only.